
    
      OBJECTIVES:

        -  Determine the response in patients with stage IVB, recurrent, or persistent cervical
           cancer treated with isotretinoin, interferon alpha-2b, and paclitaxel.

      OUTLINE: This is a multicenter study.

      Patients receive oral isotretinoin and interferon alpha-2b subcutaneously once daily on days
      1-4 and paclitaxel IV over 3 hours on day 4. Courses repeat every 21 days in the absence of
      disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 27-66 patients will be accrued for this study.
    
  